文献速递胰腺与胆道疾病消化内镜消化道肿瘤与早癌

超声内镜引导下胆管十二指肠吻合术与ERCP预防恶性远端胆道梗阻术后胰腺炎的比较:一项随机试验

Endoscopic Ultrasound-Guided Choledochoduodenostomy vs Endoscopic Retrograde Cholangiopancreatography in Malignant Distal Biliary Obstruction to Prevent Postprocedural Pancreatitis: A Randomized Trial.
PubMed 文献 · Gastroenterology · 2026-01-09

这项多中心随机优效性试验纳入220例恶性远端胆道梗阻伴胆总管扩张(≥15 mm)患者,比较EUS-CDS与ERCP作为初次胆道引流。EUS-CDS组术后急性胰腺炎风险低于ERCP组(1.8% vs 7.3%;RR 0.25;95%CI 0.07-0.88),技术成功率更高(94.6% vs 78.9%;

要点

  • EUS-CDS较ERCP显著降低术后急性胰腺炎风险(1.8% vs 7.3%;RR 0.25;95%CI 0.07-0.88)。
  • 两组其他不良事件、临床成功率、支架通畅率及总生存无显著差异。

核心结论

  • EUS-CDS在降低术后急性胰腺炎风险方面优于ERCP,但总体不良事件风险无显著差异。
  • EUS-CDS技术成功率更高且临床疗效相当,支持其作为胆总管扩张的选定患者的潜在首选方法。

研究设计与样本

  • 多中心随机优效性试验,纳入因恶性远端胆道梗阻伴胆总管扩张(≥15 mm)所致梗阻性黄疸的连续患者。
  • 共220例患者随机分配至EUS-CDS组(111例)或ERCP组(109例)接受初次胆道引流,按意向性治疗原则分析。

主要发现

  • EUS-CDS组术后急性胰腺炎发生率为1.8%,ERCP组为7.3%(RR 0.25;95%CI 0.07-0.88)。
  • 其他不良事件发生率EUS-CDS组为19.8%,ERCP组为21.1%(RR 0.94;95%CI 0.56-1.58)。
  • 临床成功率、6个月支架通畅率及总生存率两组无差异。

关键数值与推荐

  • 纳入标准:恶性远端胆道梗阻所致梗阻性黄疸,胆总管扩张≥15 mm。
  • 主要结局为术后急性胰腺炎;次要结局包括技术成功、临床成功、不良事件、6个月支架通畅率和总生存。

临床怎么用

  • 对于胆总管扩张(≥15 mm)的恶性远端胆道梗阻患者,EUS-CDS可作为初次胆道引流的可选方案以降低术后胰腺炎风险。
  • EUS-CDS技术成功率较高且操作时间较短,但需注意总体不良事件风险与ERCP相当。

局限性

  • 总体不良事件风险无显著差异,需进一步研究。
  • 研究仅纳入胆总管扩张≥15 mm的选定患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Postprocedural pancreatitis is the most common adverse event (AE) associated with endoscopic retrograde cholangiopancreatography (ERCP). Endoscopic ultrasound-guided choledochoduodenostomy (EUS-CDS) using a lumen-apposing metal stent is emerging as a promising approach for managing malignant distal biliary obstruction, offering the potential to lower the risk of postprocedural pancreatitis. METHODS: This was a multicenter randomized study, enrolling consecutive patients admitted for obstructive jaundice due to malignant distal biliary obstruction with dilated common bile duct (≥15 mm). Patients were randomly allocated to receive EUS-CDS or ERCP for primary biliary drainage. This was a superiority trial with postprocedural acute pancreatitis as primary outcome. Other outcomes included technical success, clinical success, AEs, 6-month stent patency rate, and overall survival. Analyses were performed according to intention-to-treat principles. RESULTS: Between April 2021 and October 2023, 220 patients were enrolled in the study (EUS-CDS, 111; ERCP, 109). EUS-CDS group showed a lower risk for postprocedural acute pancreatitis (1.8% in EUS-CDS vs 7.3% in ERCP; relative risk, 0.25; 95% confidence interval, 0.07-0.88). Technical success was achieved in 94.6% in EUS-CDS group vs 78.9% ERCP group (P < .001), in a mean procedural time of 13.5 ± 11.6 minutes and 24.7 ± 14.9 minutes, respectively (P <.001). No differences were found in other AEs (19.8% in EUS-CDS vs 21.1% in ERCP; relative risk, 0.94; 95% confidence interval, 0.56-1.58), clinical success, stent patency, or overall mortality. CONCLUSIONS: EUS-CDS is superior to ERCP in reducing postprocedural acute pancreatitis risk. However, the overall risk of AEs was not significantly different and warrants further investigation. Additionally EUS-CDS showed improved technical success and comparable clinical efficacy. These results support a potential role of EUS-CDS as primary approach in selected patients with dilated common bile duct (ClinicalTrials.gov, Number: NCT04099862).

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Anderloni A, Spadaccini M, Binda C, et al. Endoscopic Ultrasound-Guided Choledochoduodenostomy vs Endoscopic Retrograde Cholangiopancreatography in Malignant Distal Biliary Obstruction to Prevent Postprocedural Pancreatitis: A Randomized Trial. Gastroenterology. 2026. PMID: 41511419. doi:10.1053/j.gastro.2025.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。